FC Fusion Protein Market: Industry Trends and Global Forecasts -Distribution by Target Indications, Type of Fusion Molecule, Route of Administration and Key Geographical Regions

GLOBAL FC FUSION PROTEIN MARKET: GROWTH AND TRENDS

GLOBAL FC FUSION PROTEIN MARKET: KEY INSIGHTS

The report delves into the current state of global Fc fusion protein market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, around 40 players from across the world, are engaged in evaluating the potential benefits of Fc fusion therapeutics for the treatment of a wide range of disease indications.
• The pipeline features 115+ drug therapies being evaluated either as monotherapies or in combination with other interventions across different stages of development; most of these are designed for parenteral administration.
• Majority of the approved therapies and late-stage candidates are intended for the treatment of various oncological disorders, genetic disorders, hematological disorders and immunological disorders.
• Given the therapeutic benefits of fc fusion, these interventions are primarily evaluated as monotherapies; examples of late-stage drugs being investigated as monotherapy include ACE-011 and RC18.
• Around 50% of the fc fusion therapeutics are meant for subcutaneous administration; these can be self-administered by the patients using different drug delivery systems.
• Over two million patients have been enrolled in the clinical studies being conducted for the evaluation of close to 120 fc fusion-based therapy candidates, across various geographies.

• Several organizations have extended financial support to aid research efforts in this domain; currently, the focus, in terms of funds disbursed, is primarily in support of investigations of drugs for non-SBIR / STTR purposes.
• The number of grants awarded to stakeholders in this domain has increased in the past few years; more than 60% of the total amount was awarded for research projects.
• The field has witnessed the involvement of various administering institutes of the NIH; of all the institutes, participation of the NCI, NIAID, and NHLBI has been relatively more prominent.
• Over time, the intellectual property related to Fc fusion therapeutics has grown at a commendable pace, with patents being filed by both industry and non-industry players.
• Number of patents filed / granted in this domain have increased at a CAGR of 17% during the given time period, with majority of the patents filed / granted in the past two years.
• In addition to industry players, several academic organizations, such as Stanford University and INSERM have also filed patents related to fc fusion therapeutics.
• The high value patents focus on the modification of Fc region with different fusion molecules, such as receptor ECD, enzyme and peptide.
• Published scientific literature is indicative of the ongoing pace of research in this field; the focus of past and ongoing studies seems to be fixated on the development of anti-cancer therapeutics.
• The past few years have seen a steady rise in the number of publications related to fc fusion therapeutics; these include articles highlighting the type of biological moieties fused with the Fc region of the antibodies.
• Majority (~70%) of the published articles are related to the research studies focused on evaluating the therapeutic potential of Fc fusion proteins across various oncological and blood disorders.
• Articles related to Fc fusion therapeutics have been published in several high impact journals; however, PLoS One and MAbs have emerged as the key journals with over 30 articles.
• With multiple pipeline candidates in the mid to late stages of development, these interventions are primarily targeting oncological disorders; majority of these are Fc protein engineered antibodies.
• A number of marketed drugs, such as Fasenra, Gazyva, Margenza and Skyrizi, are now being evaluated for their efficacy across other oncological indications as well.
• Majority (~60%) of the late-stage candidates are targeting oncological indications, including solid tumors, non-Hodgkin lymphoma, and non-small cell lung cancer.
• Driven by an increasing number of late-stage therapies in the pipeline, the future opportunity, in terms of revenues, is anticipated to grow at a notable annualized rate during the forecast period.

• The estimated market opportunity is expected to be well-distributed across different types of therapies, target indications, type of fusion molecules, routes of administration and key geographic regions.

Example Players in the Fc Fusion Protein Market

• AbbVie
• Akesobio
• Alexion Pharmaceuticals
• Amgen
• AstraZeneca
• Boehringer Ingelheim
• Genentech
• MacroGenics
• MorphoSys
• Kyowa Kirin
• Xencor

GLOBAL FC FUSION PROTEIN MARKET

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global Fc fusion protein market, focusing on key market segments, including [A] target indications, [B] type of fusion molecule, [C] route of administration and [D] key geographical regions.
• Market Landscape: A comprehensive evaluation of Fc fusion therapeutics, considering various parameters, such as [A] phase of development of lead candidates, [B] type of fusion molecule, [C] target gene, [D] therapeutic area(s), [E] target disease indication(s), [F] type of therapy, [G] route of administration and [H] dosing frequency. Additionally, a detailed evaluation of the drug developer(s), based on [A] year of establishment, [B] company size, and [C] location of headquarters.
• Company Profiles: In-depth profiles of companies engaged in the development of Fc fusion therapeutics, focusing on [A] company overview, [B financial information (if available), [C] product portfolio and [D] recent developments and an informed future outlook.
• Clinical Trial Analysis: A detailed analysis of clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as [A] trial registration year, [B] trial phase, [C] study design, [D] type of masking, [E] type of intervention model, [F] emerging focus area, [G] leading industry sponsors / collaborators, [H] popular indications, [I] popular interventions and [J] regional distribution of trials.
• Grant Analysis: An in-depth analysis of grants that have been awarded to research institutes engaged in conducting projects related to Fc fusion therapeutics, based on various relevant parameters, such as [A] year of grant award, [B] amount awarded, [C] administering institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code and [H] emerging focus areas.
• Publication Analysis: A comprehensive analysis of close to 1,135 peer-reviewed scientific articles related to Fc fusion therapeutics, based on [A] year of publication, [B] emerging focus areas, [C] target therapeutic area, [D] leading authors and [E] key journals.
• Patent Analysis: An in-depth analysis of patents filed / granted related to Fc fusion therapeutics, based on various relevant parameters, such as [A] publication year, [B] geography, [C] CPC symbols, [D] emerging focus areas, [E] type of applicant, [F] leading industry players and [G] patent valuation analysis.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] focus area, [D] type of partner, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
• Case Study: A detailed discussion on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as [A] phase of development, [B] target disease indication, [C] therapeutic area, [D] type of Fc engineering, [E] impact of Fc engineering, [F] route of administration and [G] type of therapy.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with the Research Team
• Free Update if the Report is 6+ Months Old